|
|
|
|
|
Decamethonium
drug data and news
Decamethonium drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Decamethonium | ||
| Brand Names/Synonyms | BRN 1774794; DECAMETHONIUM; Decamethonium; Decamethonum; HSDB 3221; Syncurine | ||
| Indication | For use as a skeletal muscle relaxant | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Decamethonium acts as a depolarizing muscle relaxant or neuromuscular blocking agent. It acts as an agonist of nicotinic acetycholine receptors in the motor endplate and causes depolarization. This class of drugs has its effect at the neuromuscular junction by preventing the effects of acetylcholine. Normally, when a nerve stimulus acts to contract a muscle, it releases acetylcholine. The binding of this acetylcholine to receptors causes the muscle to contract. Muscle relaxants play an important role in anesthesia even though they don't provide any pain relief or produce unconsciousness. | ||
| Mechanism Of Action | Binds to the nicotinic acetycholine receptors (by virtue of its similarity to acetylcholine) in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrance remains depolarized and unresponsive to any other impulse, causing muscle paralysis. | ||
| Decamethonium News (When available) |
| ||
| Dosage Forms | Not Available | ||
| Drug_Category | Neuromuscular Depolarizing Agents; ATC:M03 | ||
| Absorption | Rapidly absorbed. | ||
| Interactions |
Interactions for Decamethonium: Potentially fatal drug interactions may occur when coadministered with digoxin, as this may enhance cardiovascular depression and bradyarrhythmias may occur. Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression. In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline. | ||
| Toxicity | Oral, mouse LD50: 190 mg/kg. Prolonged apnoea, neuromuscular paralysis and cardiac arrest may occur. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | trimethyl-(10-trimethylammoniodecyl)ammonium | ||
| Chemical Formula | C16H38N2 | ||
| Molecular Weight | 258.486 g/mol | ||
| Smiles String | C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C | ||
| Melting Point | 268-270 °C | ||
| Water Solubility | Substantial | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | Not Available | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00696 | ||
| CAS Registry Number | 156-74-1 | ||
| KEGG Compound ID | C11733 | ||
| PubChem ID | SID:13898 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |